Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers
Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific Advisory Board (SAB). Dr Lammers, an entrepreneur in the therapeutic oligonucleotide field, will work together with other members of the Cristal Therapeutics SAB to provide strategic guidance and support the continued development of the Company’s programs, including those focused on oligonucleotide therapeutics.
Cristal Therapeutics is utilizing its proprietary CriPec® technology platform to develop a pipeline of targeted nanomedicines with superior therapeutic profiles. The Company’s lead drug candidate, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several oncology products in preclinical discovery that incorporate therapeutic oligonucleotides. These are designed to overcome the major shortcomings of current oligonucleotide therapies, and are customised to enable the controlled and sustained release of a therapeutic payload at the disease site.
Dr Joost Holthuis, Cristal Therapeutic’s CEO and Co-founder said:
”We are pleased to welcome Paul, who has a deep scientific and clinical understanding of the therapeutic oligonucleotide arena and its market potential, to the Cristal Therapeutics’ SAB. We look forward to working with Paul. His immense expertise and experience will be very valuable as we continue to advance our preclinical oligonucleotide programs towards clinical development and maximize the potential of these therapeutic oligonucleotide modalities.”
Dr Paul Lammers is currently Chief Executive Officer of Mirna Therapeutics. Previously, he served as President of Repros Therapeutics Inc., a biopharmaceutical company, after having served for 6 years as the Chief Medical Officer for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Having worked actively in senior roles across the Pharma and Biotech industries for the past 25 years, Dr Lammers has gained therapeutic experiences in women’s and men’s health, neurodegenerative diseases, metabolic disorders, orphan drug diseases, and oncology. Dr Lammers received a M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.
Other members of Cristal Therapeutics SAB can be found here: (https://cristaltherapeutics.com/about-us/scientific-advisory-board/)
Cristal Therapeutics is a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customised nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.
The Company’s lead product, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several other products in preclinical development targeting cancer and inflammatory diseases.
Cristal Therapeutics is a private company that has raised over Euro 19M to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.